Laurus Labs Limited (LAURUSLABS.BO)
INR 579.2
(3.34%)
INR 579.2
(3.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8 Billion INR | -48.33% |
| 2022 | 15.75 Billion INR | 10.29% |
| 2021 | 14.27 Billion INR | -9.7% |
| 2020 | 15.72 Billion INR | 181.44% |
| 2019 | 5.59 Billion INR | 56.31% |
| 2018 | 3.6 Billion INR | -17.75% |
| 2017 | 4.35 Billion INR | 0.25% |
| 2016 | 4.38 Billion INR | 20.93% |
| 2015 | 3.66 Billion INR | 71.48% |
| 2014 | 2.24 Billion INR | 0.9% |
| 2013 | 2.14 Billion INR | 42.39% |
| 2012 | 1.44 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.71 Billion INR | -38.6% |
| 2024 Q2 | 1.82 Billion INR | 14.58% |
| 2023 Q3 | 1.83 Billion INR | -3.06% |
| 2023 FY | - INR | -48.33% |
| 2023 Q2 | 1.89 Billion INR | 11.35% |
| 2023 Q1 | 1.7 Billion INR | -30.47% |
| 2023 Q4 | 2.6 Billion INR | 41.43% |
| 2022 Q3 | 4.05 Billion INR | -10.0% |
| 2022 Q1 | 4.55 Billion INR | 22.77% |
| 2022 Q4 | 2.44 Billion INR | -39.51% |
| 2022 FY | - INR | 10.29% |
| 2022 Q2 | 4.5 Billion INR | -1.29% |
| 2021 Q4 | 3.71 Billion INR | 27.79% |
| 2021 Q2 | 3.47 Billion INR | -13.28% |
| 2021 Q3 | 2.9 Billion INR | -16.47% |
| 2021 FY | - INR | -9.7% |
| 2021 Q1 | 4.01 Billion INR | -13.66% |
| 2020 Q2 | 3.78 Billion INR | 32.79% |
| 2020 Q3 | 4.33 Billion INR | 14.31% |
| 2020 Q4 | 4.64 Billion INR | 7.26% |
| 2020 FY | - INR | 181.44% |
| 2020 Q1 | 2.85 Billion INR | 61.02% |
| 2019 Q4 | 1.77 Billion INR | 18.09% |
| 2019 Q1 | 877.6 Million INR | -11.93% |
| 2019 Q2 | 1.39 Billion INR | 58.58% |
| 2019 Q3 | 1.5 Billion INR | 7.85% |
| 2019 FY | - INR | 56.31% |
| 2018 Q1 | 831.4 Million INR | -31.83% |
| 2018 FY | - INR | -17.75% |
| 2018 Q4 | 996.5 Million INR | 11.8% |
| 2018 Q3 | 891.3 Million INR | 3.33% |
| 2018 Q2 | 862.54 Million INR | 3.75% |
| 2017 Q3 | 972.92 Million INR | -18.38% |
| 2017 Q4 | 1.21 Billion INR | 25.36% |
| 2017 FY | - INR | 0.25% |
| 2017 Q1 | 1.04 Billion INR | -16.93% |
| 2017 Q2 | 1.19 Billion INR | 14.56% |
| 2016 Q1 | 873.09 Million INR | 0.0% |
| 2016 Q4 | 1.25 Billion INR | 11.54% |
| 2016 FY | - INR | 20.93% |
| 2016 Q3 | 1.12 Billion INR | -3.34% |
| 2016 Q2 | 1.16 Billion INR | 33.08% |
| 2015 FY | - INR | 71.48% |
| 2014 FY | - INR | 0.9% |
| 2013 FY | - INR | 42.39% |
| 2012 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 16.749% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 87.043% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -16.657% |
| Granules India Limited | 8.6 Billion INR | 6.948% |
| Indoco Remedies Limited | 2.64 Billion INR | -202.449% |
| Achyut Healthcare Limited | 524 Thousand INR | -1527762.595% |
| Ajanta Pharma Limited | 12.56 Billion INR | 36.285% |
| Alkem Laboratories Limited | 24.19 Billion INR | 66.911% |
| Alpa Laboratories Limited | 86.12 Million INR | -9195.575% |
| Brooks Laboratories Limited | 41.72 Million INR | -19086.158% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -239.698% |
| Bajaj HealthCare Limited | 444.51 Million INR | -1701.06% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -441.301% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 90.931% |
| Eris Lifesciences Limited | 6.98 Billion INR | -14.593% |
| FDC Limited | 4.4 Billion INR | -81.885% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 29.423% |
| Gufic Biosciences Limited | 1.48 Billion INR | -440.768% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -16.678% |
| Ipca Laboratories Limited | 13.29 Billion INR | 39.802% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2375.113% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 9777.614% |
| Lasa Supergenerics Limited | -65.08 Million INR | 12401.782% |
| Lupin Limited | 36.96 Billion INR | 78.344% |
| Mankind Pharma Limited | 28.09 Billion INR | 71.503% |
| Medicamen Biotech Limited | 245.66 Million INR | -3158.976% |
| Medico Remedies Limited | 150.37 Million INR | -5223.917% |
| Megasoft Limited | 284.73 Million INR | -2711.777% |
| NATCO Pharma Limited | 18.79 Billion INR | 57.404% |
| Piramal Pharma Limited | 13.05 Billion INR | 38.677% |
| RPG Life Sciences Limited | 1.28 Billion INR | -524.737% |
| Sigachi Industries Limited | 883.39 Million INR | -806.273% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 94.214% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -71.171% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1760.666% |
| Unichem Laboratories Limited | 742.35 Million INR | -978.458% |
| Wanbury Limited | 985.49 Million INR | -712.388% |
| Windlas Biotech Limited | 781.72 Million INR | -924.152% |
| ZIM Laboratories Limited | 462.09 Million INR | -1632.537% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 85.76% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 314.565% |
| Divi's Laboratories Limited | 25.43 Billion INR | 68.517% |
| Hester Biosciences Limited | 539.47 Million INR | -1384.049% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -165.592% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -1072.975% |
| Bal Pharma Limited | 345.59 Million INR | -2216.605% |
| Strides Pharma Science Limited | 3.76 Billion INR | -112.661% |
| Venus Remedies Limited | 711.8 Million INR | -1024.753% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -104.787% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -411.961% |
| Shilpa Medicare Limited | 2.58 Billion INR | -209.353% |
| Aarti Drugs Limited | 3.24 Billion INR | -146.442% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -207.143% |
| Suven Life Sciences Limited | -992.78 Million INR | 906.422% |
| Ind-Swift Limited | 1.06 Billion INR | -651.691% |
| Valiant Laboratories Limited | 12.73 Million INR | -62746.377% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 14.235% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 383.71% |
| Themis Medicare Limited | 562.6 Million INR | -1323.018% |
| Hikal Limited | 2.69 Billion INR | -197.374% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 77.132% |
| Sequent Scientific Limited | 549.8 Million INR | -1356.166% |
| Novartis India Limited | 1.26 Billion INR | -530.741% |
| Wockhardt Limited | 1.08 Billion INR | -641.296% |
| Jubilant Pharmova Limited | 8 Billion INR | 0.0% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -61192.298% |
| Neuland Laboratories Limited | 4.74 Billion INR | -68.612% |
| Morepen Laboratories Limited | 1.72 Billion INR | -363.859% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -2685.422% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -4476.269% |